• Explore /
  • Poster
  • / TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL).

TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL).

Abstract Poster

Authors

Krish Patel

Krish Patel

Swedish Cancer Institute, Seattle, WA

Krish Patel , Dahlia Sano , Michael Maris , Alexander M. Lesokhin , Gottfried Von Keudell , Kimberley Doucette , Radhakrishnan Ramchandren , Dmitri Pavlov , Robert A. Uger , Naomi Molloy , Ingmar Bruns , Anita Scheuber , Swaminathan Padmanabhan Iyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03530683

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS7595)

DOI

10.1200/JCO.2022.40.16_suppl.TPS7595

Abstract #

TPS7595

Poster Bd #

239a

Abstract Disclosures

Similar Posters

First Author: Krish Patel

First Author: Bong-Seog Kim

First Author: Connie Lee Batlevi

First Author: Dejan Juric